Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA-based vaccines

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Investment Bank

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 06, 2020

            Details:

            The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA-based vaccines

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Tesla

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 02, 2020

            Details:

            CureVac has reportedly snared a big partner to help build its game-changing RNA "printers" that could turn global interest back in its favor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Temasek

            Deal Size: $250.0 million Upfront Cash: $139.0 million

            Deal Type: Funding June 29, 2020

            Details:

            BioNTech is expected to post data from its Phase I/II trial virtually any day now, as analysts expect some hard numbers on immunogenicity and safety for BNT162 in the June/July time frame.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 17, 2020

            Details:

            German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for CureVac's vaccine program to prevent SARS-CoV-2 infection.